MNX Adds New Board Member, Seeking to Accelerate Growth in Pharmaceutical and Clinical Trial Logistics

USA - English

• Latin America - español
• Brazil - Português

LOS ANGELES, June 24, 2013 /PRNewswire/ -- MNX, a global provider of expedited transportation and logistics services, is pleased to announce the appointment of Renzo DiCarlo to its board of directors. This appointment comes as MNX is accelerating its strategy to grow in the life sciences sector with particular focus on pharmaceutical and clinical trial logistics in the EMEA and Asia Pacific regions. 

(Logo: http://photos.prnewswire.com/prnh/20130624/LA36380LOGO)

DiCarlo is a 20 year veteran of the pharmaceutical industry with broad experience delivering first-in world FDA approved therapeutic drugs and medical devices. As CEO of BioPharma Services, DiCarlo leads a team of over 200 Life Science professionals based in Toronto, Canada with affiliate partners in Europe and Asia, providing clinical trials research (Phases I-IIa), bioequivalence, pharmaceuticals, regulatory data management and statistical services, to leading generic and brand-name pharmaceutical companies worldwide. His teams are involved in the management of numerous studies each year in important research areas, including orthopedics, dermatology, arthritis, diabetes, oncology, and other critical diseases.

"DiCarlo's deep knowledge of the pharmaceutical industry and history of success at the executive and board level will help bolster MNX's growth strategy," said Scott Cannon, CEO, MNX. "He brings to the board a valuable network of industry contacts and a vast experience dealing with international biopharmaceutical companies. We are incredibly excited to have him join the MNX board."

"I am thrilled to be a member of this exciting and fast moving company. I like the entrepreneurial spirit at MNX, and the strong focus it has on life sciences logistics," said DiCarlo. "With MNX and The Riverside Company, we now have the leadership team, operational know-how, and resources necessary to take the company to the next level in the medical and pharmaceutical logistics space. I believe I can bring hands-on top tier executive experience to the MNX Board in the areas of pharmaceutical, clinical, and medical laboratory work to enhance and deepen our discussions at the Board level."

In the past year MNX has been aggressively building its capabilities and expanding its customer portfolio. This announcement comes as one in a series of significant appointments and global office openings across the Americas, Europe and Asia Pacific. MNX continues to position itself as the premier provider of specialized logistics services serving a broad range of customers in the life sciences, biopharmaceutical, medical device, clinical research, aviation AOG and entertainment industries.

About MNX
MNX is a premier global provider of specialized, expedited transportation and logistics services. Clients include multinational leaders in biopharmaceutical, life sciences, medical device, aviation and entertainment industries. These organizations rely on MNX's exceptional record of transporting critical items around the world.

Headquartered in Los Angeles, MNX maintains regional headquarters in Singapore and London. MNX serves over 190 countries, including key Asia Pacific and EMEA markets. Services include dedicated hand-carry, first-flight-out, charter, express courier and 4PL services management. www.mnx.com

Media Contact:
Ken Ying
MNX
+1.310.981.0919
[email protected]

SOURCE MNX